2:01 PM
 | 
Jul 12, 2018
 |  BC Extra  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications.

Immatics will receive $54 million up front and is eligible for $550 million in milestones for each product the partners develop, plus royalties up to double digits. Genmab may opt to add two additional targets.

The partners will seek to develop therapies using Immatics' Bispecific TCR platform, with which the biotech creates molecules with two binding domains. One is a TCR domain that binds to a tumor peptide antigen presented on an HLA molecule. The other is a T cell-recruiting antibody domain against an immuno-modulating T cell surface protein such as CD3. The design activates T cells against a tumor, regardless of their intrinsic specificity, Immatics said.

The companies are choosing targets via Immatics' XPRESIDENT platform, with which Immatics identifies tumor-associated peptide candidates. Genmab will contribute its own antibody development expertise, which includes its DuoBody bispecific platform.

Genmab will fund R&D, manufacturing and commercialization of candidates developed under the deal. Immatics may opt to co-promote products in select EU countries.

Immatics also has a deal with Amgen Inc. (NASDAQ:AMGN) to develop T cell-engaging bispecific immunotherapies. In that partnership, announced in early 2017, Immatics received $30 million up front and is eligible for $500 million in milestones per program, plus royalties (see "Amgen, Immatics in Bispecifics Deal").

At least one other company, ImmunoCore Ltd. (Abingdon, U.K.), is developing bispecific molecules that incorporate CD3 antibody fragments and TCR components to redirect T cells against tumors.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD